Boston Scientific layoffs, on the record
Every job cut, severance charge and restructuring Boston Scientific reported in its annual reports, 2023 to 2025, quoted from the filings. Headcount went from approximately 48,000 to approximately 59,000.
Headcount, as reported
| Annual report | Employees | As of |
|---|---|---|
| 10-K for 2023 | approximately 48,000 | December 31, 2023 |
| 10-K for 2024 | approximately 53,000 | December 31, 2024 |
| 10-K for 2025 | approximately 59,000 | December 31, 2025 |
Job cuts, severance and restructuring
Our summaryBoard approved a new global restructuring program, the 2023 Restructuring Plan, with expected limited role reductions and a total estimated pre-tax charge range.
Word for word“The 2023 Restructuring Plan is expected to result in 23 total pre-tax charges of approximately $450 million to $550 million and reduce gross annual pre-tax expenses by approximately $225 million to $275 million as program benefits are realized.” 10-K for 2023
Our summaryCompany recorded restructuring charges under the 2023 Restructuring Plan, plus restructuring-related charges, in 2023.
Word for word“Pursuant to the 2023 Restructuring Plan, we recorded restructuring charges in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 420, Exit or Disposal Cost Obligations of $69 million in 2023.” 10-K for 2023
Our summaryCompany expects termination benefits and other charges under the 2023 Restructuring Plan, with costs for employee-related actions estimated by type.
Word for word“Termination benefits (1) $60 - $80 Other (2) 20 - 40 Restructuring-related expenses: Transfer costs (3) 300 - 330 Other (4) 70 - 100 $450 - $550 (1) Plans detailing specific employee impacts will be developed for each affected region and business, working with employee representative bodies where required under local laws.” 10-K for 2023
Our summaryCompany reported cash outlays expected from the 2023 Restructuring Plan.
Word for word“The implementation of the 2023 Restructuring Plan is estimated to result in total pre-tax charges of approximately $450 million to $550 million, of which approximately $350 million to $450 million is expected to result in cash outlays, and reduce gross annual pre-tax expenses by approximately $225 million to $275 million as program benefits are realized.” 10-K for 2023
Our summaryCompany completed its 2019 Restructuring Plan, reporting its total charges and cash outlays, and recorded 2022 charges under it.
Word for word“The 2019 Restructuring Plan resulted in total pre-tax charges of $461 million and approximately $404 million in cash outlays.” 10-K for 2023
Our summaryThe company recorded restructuring charges and restructuring-related charges under the 2023 Restructuring Plan during 2024.
Word for word“We recorded Restructuring net charges (credits) of $ 16 million in 2024, $ 69 million in 2023 and $ 24 million in 2022.” 10-K for 2024
Our summaryThe company reported a restructuring reserve balance at year end, reflecting severance and other exit costs not yet paid.
Word for word“The restructuring reserve balance as of December 31, 2024 and 2023 was $ 26 million and $ 41 million, respectively.” 10-K for 2024
Our summaryThe 2023 Restructuring Plan includes termination benefits for affected employees, with plans developed by region and business.
Word for word“Plans detailing specific employee impacts will be developed for each affected region and business, working with employee representative bodies where required under local laws.” 10-K for 2024
Our summaryThe company committed to a global restructuring program in February 2023 to simplify its manufacturing and distribution network and expand operating efficiencies.
Word for word“The 2023 Restructuring Plan is expected to result in total pre-tax charges of approximately $700 million to $800 million and reduce gross annual pre-tax expenses by approximately $350 million to $400 million as program benefits are realized.” 10-K for 2025
Our summaryThe Board approved expanding the 2023 Restructuring Plan with up to $250 million in additional pre-tax charges for further efficiency and functional optimization activities.
Word for word“On July 29, 2025, our Board of Directors approved expanding the 2023 Restructuring Plan by up to $250 million in aggregate additional pre-tax charges, to include further related activities under the program to drive operational efficiencies and optimize functional capabilities.” 10-K for 2025
Our summaryThe company discontinued worldwide sales of the ACURATE aortic valve systems and recorded restructuring charges as a result.
Word for word“The decision resulted in total pre-tax restructuring and restructuring-related net charges of approximately $87 million in 2025.” 10-K for 2025
| Fiscal year ended | Restructuring charges | Restructuring costs incurred | Cash paid for restructuring |
|---|---|---|---|
| 2016-12-31 | $28 million | $78 million | $82 million |
| 2017-12-31 | $37 million | $95 million | $70 million |
| 2018-12-31 | $36 million | $96 million | — |
| 2019-12-31 | $38 million | — | $64 million |
| 2020-12-31 | $52 million | — | — |
| 2021-12-31 | $40 million | — | — |
| 2022-12-31 | $24 million | — | — |
| 2023-12-31 | $69 million | — | — |
| 2024-12-31 | $16 million | — | — |
| 2025-12-31 | $101 million | — | — |
Boston Scientific filed 5 restructuring notices (Form 8-K, Item 2.05) since 2016. This page shows what the company reported to the SEC, not news reports or state layoff notices.
Read from Boston Scientific’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-17. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.